Resumen de The Paradox of Precision Medicine.
The article focuses on the benefits and drawbacks of precision medicine. It comments on the cystic fibrosis drug ivacaftor which can treat around five percent of cystic fibrosis patients and was fast-tracked by the U.S. Food and Drug Administration in 2010, and mentions the drug costs 300,000 dollars a year per patient and could be treated equally using the antibiotic azithromycin, aerosolized saline, and high-dose ibuprofen. It examines the use of genetics in determining metabolism of warfarin.
